Featured Content |Content Library
Sara Tolaney, MD, MPH discusses updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0.
Dana-Farber Cancer Institute announced that The Rossy Foundation has committed $10 million to establish the David Liposarcoma Research Initiative.
T cells revved up to attack tumors are turned into an army of loiterers. Cells keenly attuned to signals of infection or disease fail to pick up the faint notes of cancer. A clinical trial led by Dana-Farber researchers is addressing both ...
Dana-Farber's Giacomo Oliveira, PhD describes a study he led with Cathy Wu, MD, that appeared in Nature.
An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows.
The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States. These findings ...